Plasma Copeptin Levels in Children With Diabetic Ketoacidosis (COPACD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.

Children with diabetic ketoacidosis risk neurological complications such as cerebral edema with high morbidity. To prevent cerebral edema, it is essential to control correction of hypovolemia, hyperglycemia and natremia. Markers usually used in management of diabetic ketoacidosis don't always permit an optimal care.

Plasma copeptin levels reflect vasopressin secretion which is high in diabetic ketoacidosis.

Therefore, monitoring of plasma copeptin levels could be of interest in children with diabetic ketoacidosis and risk of sévère neurological complications.

Condition or disease

Intervention/treatment

Diabetic Ketoacidosis Children

Other: Copeptine dosage in children with diabetic ketoacidosis at diagnosis

Detailed Description:

Biological risk factors for severe complications in diabetic ketoacidosis are described (high blood glucose level, metabolic acidosis, high blood urea nitrogen, hypernatremia) but their dosage and monitoring are not sufficient to distinguish high risks situations.

Several studies suggest that vasopressin secretion is increased in diabetic ketoacidosis. This high level could be important in occurrence of cerebral edema. Monitoring of vasopressin levels could then have an interest in patients at risk of severe complications but reliability of copeptin dosage depend of collection conditions and its packaging. These conditions are difficult to ensure and copeptin dosage, which represent vasopressin secretion, is easier to perform.

Copeptin dosage could then be a new biological marker, more accurate and specific, for an optimal management of diabetic ketoacidosis.

This type of study has never been carried out neither in children nor in adults.

Interest of copeptin dosage as a severity marker in children under the age of 16 with diabatic ketoacidosis [ Time Frame: 30 months ]

Study of correlation between copeptin levels and metabolic acidosis in the first 36 hours management of diabatic ketoacidosis in children

Secondary Outcome Measures
:

Correlation between plasma copeptin levels and other markers used in management of diabatic ketoacidosis in the first 36 hours after diagnosis- Plasma copeptin levels at diagnosis of diabate mellitus type 1 without ketoacidosis in children [ Time Frame: 30 months ]

Interest of copeptin dosage as a new marker of diabatic ketoacidosis severy compared to other used markers

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

6 Months to 16 Years (Child)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion criteria:

Children between 6 months and 16 years

Diagnosis of diabetes mellitus type 1 (cardinal syndrome, blood glucose level > 7 mmol/L in the fasted state or > 11 mmol/L not in fasted state, no signs for another type of diabetes mellitus)

Children who need an exclusive intravenous rehydration for 36 hours

Written informed consent of legal representative and of the child if possible

Beneficiary of State Social Insurance

Exclusion criteria:

Child under the age of 6 months or older than 16 years

Non exclusive intravenous réhydration for at least 36 hours

Child moved from another institution and for whom an intravenous rehydration or insulin therapy have already begun